4-乙氧基羰基甲基苯硼酸 | 92243-74-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-乙氧基羰基甲基苯硼酸
• 英文名称: [4-(2-ethoxy-2-oxoethyl)phenyl]boronic acid
• 英文别名: (4-(2-Ethoxy-2-oxoethyl)phenyl)boronic acid
• CAS: 92243-74-8
• 化学式: C₁₀H₁₃BO₄
• 分子量: 208.022
• InChiKey: RDIRUZGSOKLANG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.53
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Ethoxycarbonylmethylphenylboronic acid
Synonyms: Eltyl (4-boronophenyl)acetate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Ethoxycarbonylmethylphenylboronic acid
CAS number: 92243-74-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H13BO4
Molecular weight: 208.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-乙氧基羰基甲基苯硼酸 在 potassium phosphate 、 C₃₃H₄₉P*Pd⁽²⁺⁾*Cl^(1-)*C₄H₈^(1-) 、 三乙胺 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 104.0h， 生成 ethyl 2-(4-(4-oxo-3-phenyl-2-((1S)-1-((9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)amino)propyl)-3,4-dihydroquinazolin-5-yl)phenyl)acetate
  参考文献：
  名称：

  喹唑啉-4-酮基异羟肟酸作为PI3K / HDAC双重抑制剂的设计，合成和生物学评估。

  摘要：

  通过经由优化的接头将HDAC药效团掺入PI3K抑制剂（Idelalisib）中，合理设计和合成了一系列基于喹唑啉-4-酮的异羟肟酸，作为新型的双重PI3K / HDAC抑制剂。这些双重抑制剂中的几种非常有效（IC50 <10 nM），对PI3Kγ，δ和HDAC6酶具有选择性，并且对多种癌细胞具有良好的抗增殖活性。铅化合物48c在AML患者的几种突变型和FLT3抗性AML细胞系和原代细胞中诱导坏死，而对正常PBMC，NIH3T3和HEK293细胞无细胞毒性。使用细胞热位移分析（CETSA）在MV411细胞中证明了48c的PI3Kδ和HDAC6的靶标结合。

  DOI：

  10.1021/acs.jmedchem.0c00193
• 作为产物：
  描述：

  4-(溴甲基)苯硼酸 在 盐酸 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 4-乙氧基羰基甲基苯硼酸
  参考文献：
  名称：

  芳基硼化合物-VIII：羟基和羧苯基硼酸的一些反应

  摘要：

  羧基和羟基苯基硼酸（I-VI）的一些新的衍生物已被制备并直接卤化邻位和对位羟基和甲氧基苯基酸进行了研究。

  DOI：

  10.1016/s0040-4020(01)99333-0

文献信息

• HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US20160024031A1

  公开（公告）日：2016-01-28

  Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-4-[3-methyl-4((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

  描述了异环化合物，这些化合物是溶血磷脂酸受体配体，可用于治疗溶血磷脂酸受体依赖性疾病和状况，包括但不限于涉及纤维化的疾病，如心脏、肾脏、肝脏和肺的纤维化以及硬化病；炎症性疾病，如糖尿病肾病和炎症性肠病；眼病，如涉及视网膜变性的疾病；神经疾病，如瘙痒和疼痛。这些化合物的非限制性例子包括(RS)-3-环丙基-2-4-[3-甲基-4((R)-1-苯基-乙氧羰基氨基)-异恶唑-5-基]-苄氧基}-丙酸和(R)-1-(4′-5-[1-(2-氯-苯基)-乙氧羰基氨基]-4-氟-吡唑-1-基}-2-氟-联苯-4-基)-环丙烷甲酸。
• [EN] INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER<br/>[FR] INHIBITEURS DE LA PHOSPHOINOSITIDE 3-KINASE ET DE L'HISTONE DÉSACÉTYLASE POUR LE TRAITEMENT DU CANCER
  申请人：US HEALTH

  公开号：WO2018237007A1

  公开（公告）日：2018-12-27

  The present invention is directed to a dual inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC), including a core containing a quinazoline moiety or a quinazolin-4(3H)-one moiety, a kinase hinge binding moiety, and a histone deacetylase pharmacophore, a pharmaceutically acceptable salt thereof, a prodrug thereof, or solvate thereof. The present invention is also directed to a histone deacetylase inhibitor, including a core containing a quinazolin-4(3H)-one moiety and a histone deacetylase pharmacophore.

  本发明涉及一种磷脂酰肌醇3-激酶（PI3K）和组蛋白去乙酰化酶（HDAC）的双重抑制剂，包括一个含有喹唑啉基团或喹唑啉-4(3H)-酮基团的核心，一个激酶铰链结合基团，和一个组蛋白去乙酰化酶药效团，以及其药用盐、前药或溶剂化物。本发明还涉及一种组蛋白去乙酰化酶抑制剂，包括一个含有喹唑啉-4(3H)-酮基团和一个组蛋白去乙酰化酶药效团的核心。
• [EN] N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS<br/>[FR] ACÉTAMIDES À SUBSTITUTION N-(HÉTÉRO)ARYL, 2-(HÉTÉRO)ARYLE POUR UNE UTILISATION EN TANT QUE MODULATEURS DE LA VOIE DE SIGNALISATION WNT
  申请人：IRM LLC

  公开号：WO2010101849A1

  公开（公告）日：2010-09-10

  The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A1, A2, B, Y and Z all represent rings.

  本发明涉及公式1和2的化合物，以及使用这些化合物调节Wnt信号通路的方法，其中A1、A2、B、Y和Z都代表环。
• Development of a Scalable Synthesis of Tofogliflozin
  作者：Yoshihito Ohtake、Takashi Emura、Masahiro Nishimoto、Koji Takano、Keisuke Yamamoto、Satoshi Tsuchiya、Sang-Yong Yeu、Yasushi Kito、Nobuaki Kimura、Sunao Takeda、Masao Tsukazaki、Masatoshi Murakata、Tsutomu Sato

  DOI：10.1021/acs.joc.5b02734

  日期：2016.3.4

  An efficient and scalable synthesis of an antidiabetic drug, tofogliflozin (1), which was identified as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is described. A key factor in the synthesis of 1 was the selection of the purpose-designed protecting group, which plays a strategic role in protection, chemoselective activation, and crystalline purification. The developed and

  描述了一种高效，可扩展的抗糖尿病药物tofogliflozin（1）的合成，该药物被确定为高选择性钠葡萄糖共转运蛋白2（SGLT2）抑制剂。合成1的关键因素是选择专门设计的保护基，该保护基在保护，化学选择性活化和晶体纯化中起着战略性作用。通过开发和优化的方法，无需任何柱色谱法就可以以十克规模制备1。
• ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS
  申请人：HUTCHINSON John Howard

  公开号：US20100152257A1

  公开（公告）日：2010-06-17

  Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

  本文描述了一些对赖氨酸磷脂酸受体具有拮抗作用的化合物。还描述了包括本文描述的化合物的药物组合物和药物，以及使用这些拮抗剂的方法，单独或与其他化合物结合，用于治疗依赖或介导赖氨酸磷脂酸的疾病或病症。